

Press Release

Daiichi Sankyo Announces Rescheduling of 5-year Business Plan (FY2026 - FY2030) Presentation & Discussion

Tokyo – (March 25, 2026) – Daiichi Sankyo Company, Limited (TSE: 4568; hereafter “the Company”) today announced that it has rescheduled the 5-year Business Plan (FY2026 - FY2030) Presentation & Discussion.

1. Updated Schedule

The Presentation & Discussion originally scheduled for April 8, 2026, will now be held on May 19, 2026.

2. Reason for the Change

The Company has decided to reschedule the Discussion & Presentation following scheduling conflicts among certain members of management who are planned to be part of the event. As a result, the Company determined that proceeding on the originally scheduled date would not allow management to present the plan as comprehensively as intended.

The Company's 5-year Business Plan sets forth the key priorities and strategic directions that will guide the Company over the coming years. Given the significance of this information, the Company is committed to ensuring that senior management is able to present the plan's contents with the depth and clarity they deserve. Accordingly, the Company has determined that rescheduling the Presentation & Discussion is in the best interest of its shareholders and investors.

The Company wishes to emphasize that this change is solely attributable to scheduling constraints and does not reflect any changes in the assumptions or conditions underlying the development of the 5-year Business Plan (FY2026 - FY2030).

The Company appreciates the patience and continued support of its shareholders, investors, and other stakeholders.

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit <http://www.daiichisankyo.com/>.

Contacts:

Daiichi Sankyo Co., Ltd.
DS-PR_jp@daiichisankyo.com

Investor Relations:
DaiichiSankyoIR_jp@daiichisankyo.com